<DOC>
	<DOCNO>NCT03078647</DOCNO>
	<brief_summary>Clinical Study Evaluate Performance Profound System Treatment Cellulite .</brief_summary>
	<brief_title>Profound Split-thigh Dermal Subdermal Cellulite Treatment</brief_title>
	<detailed_description>Up 60 healthy female volunteer , seek cellulite treatment , 18 60 year age 3 investigational site . Prospective , open-label , baseline-controlled , two arm , randomize , clinical study evaluate Profound device use Dermal SubQ Cartridges minimally-invasive treatment upper thigh buttock cellulite appearance . The treatment area study subject divide two arm : 1 . Arm 1 - upper thigh/buttock leave right side body undergo single Profound treatment utilize Dermal SubQ Cartridges 2 . Arm 2 - contralateral upper thigh/buttock side body undergo single Profound treatment utilize SubQ Cartridge . Methodology describe protocol evaluate efficacy treatment carry visit .</detailed_description>
	<criteria>1 . Signed informed consent participate study . 2 . Female subject , ≥ 18 ≤ 60 year age time enrollment 3 . Fitzpatrick Skin Type I VI . 4 . Subjects seek treatment cellulite upper thigh buttock area . 5 . Subject cellulite stage II III grade use NurnbergerMuller scale classification ( Appendix III ) . 6 . Not pregnant , lactate must either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) . 7 . Negative urine pregnancy test test prior treatment last visit woman child bear potential ( e.g . menopause ) . 8 . General good health confirm medical history skin examination treat area . 9 . Willing receive propose Profound treatment . 10 . Willing follow treatment followup schedule posttreatment care instruction . 11 . Willing photograph image take treated area use deidentified evaluation , publication presentation . 1 . Subject cellulite stage 0 I grade use NurnbergerMuller scale classification ( Appendix III ) . 2 . Subject surgery procedure cellulite last 6 month . 3 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding . 4 . Known allergy lidocaine epinephrine antibiotic . 5 . Active malignancy history malignancy past 5 year . 6 . Having active electrical implant anywhere body , pacemaker internal defibrillator . 7 . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , lupus , porphyria , pertinent neurological disorder ( i.e . disease state opinion Physician would interfere anesthesia , treatment , heal process ) . 8 . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) . 9 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication . 10 . Suffering hormonal imbalance , whether related thyroid , pituitary , androgen . 11 . History significant lymphatic drainage problem . 12 . History cancer require lymph node biopsy dissection . 13 . Suffering significant skin condition treatment area inflammatory skin condition , include , limited , open laceration abrasion , hidradenitis , dermatitis treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course . 14 . History keloid scarring , abnormal wound heal / prone bruising . 15 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) , include collagen vascular disease vasculitic disorder . 16 . Use isotretinoin ( Accutane ) within 6 month treatment study . 17 . Subject systemic corticosteroid therapy 6 month prior throughout course study . 18 . Dysplastic nevi area treat . 19 . Participation study another device drug within 3 month prior enrollment study . 20 . Subject palpable lymphadenopathy visit . Standard palpation technique use . 21 . Subjects history severe edema . 22 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>